Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
GSK-1614235 and KGA-2727 are potent, selective inhibitors of the SGLT1 sodium-dependent glucose transporter. Nonclinical (KGA-2727) and clinical (GSK-1614235) trials assessed translation of SGLT1 inhibitor effects from rats to normal human physiology. In rats, KGA-2727 (0.1 mg/kg) or vehicle was given before oral administration of 3- O-methyl-α-d-glucopyranose (3- O-methylglucose, 3-OMG) containing 3-[3 H]OMG tracer. Tracer absorption and distribution were assessed from plasma, urine, and fecal samples. SGLT1 inhibition reduced urine 3-OMG recovery and increased fecal excretion. SGLT1 inhibitor effects on plasma glucose, insulin, gastric inhibitory peptide (GIP), and glucagon-like peptide-1 (GLP-1) concentrations were also measured during a standard meal. Incremental glucose, insulin, and GIP concentrations were decreased, indicating downregulation of β-cell and K cell secretion. Minimal effects were observed in the secretion of the L cell product, GLP-1. With the use of a three-way, crossover design, 12 healthy human subjects received placebo or 20 mg GSK-1614235 immediately before or after a meal. Five minutes into the meal, 3-OMG was ingested. Postmeal dosing had little impact, yet premeal dosing delayed and reduced 3-OMG absorption, with an AUC 0–10 of 231 ± 31 vs. 446 ± 31 μg·h−1·ml−1, for placebo. Recovery of tracer in urine was 1.2 ± 0.7 g for premeal dosing and 2.2 ± 0.1 g for placebo. Incremental concentrations of insulin, C-peptide, and GIP were reduced for 2 h with premeal GSK-1614235. Total GLP-1 concentrations were significantly increased, and a trend for increased peptide YY (PYY) was noted. SGLT1 inhibitors block intestinal glucose absorption and reduce GIP secretion in rats and humans, suggesting SGLT1 glucose transport is critical for GIP release. Conversely, GLP-1 and PYY secretion are enhanced by SGLT1 inhibition in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Human Sodium Glucose Transporters
Wright, E. M., Loo, D. D. F., & Hirayama, B. A. (2011) · Physiological Reviews · doi:10.1152/physrev.00055.2009 · Cited by 1,430
Glucose Tolerance and Cardiovascular Mortality: Comparison of Fasting and 2-Hour Diagnostic Criteria
(2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.3.397 · Cited by 1,371
Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1.
Jang, H.-J., Kokrashvili, Z., Theodorakis, M. J., Carlson, O. D., Kim, B.-J., Zhou, J., Kim, H. H., Xu, X., Chan, S. L., Juhaszova, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706890104 · Cited by 995
T1R3 and gustducin in gut sense sugars to regulate expression of Na + -glucose cotransporter 1
Margolskee, R. F., Dyer, J., Kokrashvili, Z., Salmon, K. S. H., Ilegems, E., Daly, K., Maillet, E. L., Ninomiya, Y., Mosinger, B., & Shirazi-Beechey, S. P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706678104 · Cited by 882
Glucose Sensing in L Cells: A Primary Cell Study
Reimann, F., Habib, A. M., Tolhurst, G., Parker, H. E., Rogers, G. J., & Gribble, F. M. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.11.002 · Cited by 733
Elliott, R. M., Morgan, L. M., Tredger, J. A., Deacon, S., Wright, J., & Marks, V. (1993) · Journal of Endocrinology · doi:10.1677/joe.0.1380159 · Cited by 695
Active sugar transport in health and disease
Wright, E. M., Hirayama, B. A., & Loo, D. F. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01746.x · Cited by 627
O’Keefe, J. H., & Bell, D. S. H. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.107 · Cited by 538
Parker, H. E., Habib, A. M., Rogers, G. J., Gribble, F. M., & Reimann, F. (2009) · Diabetologia · doi:10.1007/s00125-008-1202-x · Cited by 324
Balen, D., Ljubojević, M., Breljak, D., Brzica, H., Z̆lender, V., Koepsell, H., & Sabolić, I. (2008) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00180.2008 · Cited by 166
Cited by
Effects of sotagliflozin added to insulin in patients with type 1 diabetes
Garg, S. K., Henry, R. R., Banks, P., Buse, J. B., Davies, M. J., Fulcher, G. R., Pozzilli, P., Gesty-Palmer, D., Lapuerta, P., Simó, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708337 · Cited by 417
Development of SGLT1 and SGLT2 inhibitors
Rieg, T., & Vallon, V. (2018) · Diabetologia · doi:10.1007/s00125-018-4654-7 · Cited by 377
Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology
Ferrannini, E. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.011 · Cited by 340
Glucose transporters in the small intestine in health and disease
Koepsell, H. (2020) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-020-02439-5 · Cited by 290
Hyperinsulinemia: An Early Indicator of Metabolic Dysfunction
Thomas, D. D., Corkey, B. E., Istfan, N. W., & Apovian, C. M. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00065 · Cited by 259
Buse, J. B., Garg, S. K., Rosenstock, J., Bailey, T. S., Banks, P., Bode, B. W., Danne, T., Kushner, J. A., Lane, W. S., Lapuerta, P., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0343 · Cited by 234
Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport
Mudaliar, S., Polidori, D., Zambrowicz, B., & Henry, R. R. (2015) · Diabetes Care · doi:10.2337/dc15-0642 · Cited by 225
“A selective SGLT1 inhibitor was tested in a phase 1 study in 12 subjects and showed that SGLT1 inhibitors block intestinal glucose absorption, reduce GIP secretion, and enhance GLP-1 and peptide YY (PYY) secretion (27).”
MethodJeukendrup, A. E. (2017) · Sports Medicine · doi:10.1007/s40279-017-0690-6 · Cited by 208
Goldenberg, R. M., Gilbert, J. D., Hramiak, I. M., Woo, V. C., & Zinman, B. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13811 · Cited by 114
Intestinal SGLT1 in metabolic health and disease
Lehmann, A., & Hornby, P. J. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00068.2016 · Cited by 104
Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk
Seidelmann, S. B., Feofanova, E., Yu, B., Franceschini, N., Claggett, B., Kuokkanen, M., Puolijoki, H., Ebeling, T., Perola, M., Salomaa, V., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.07.061 · Cited by 97
Fukudo, S., Endo, Y., Hongo, M., Nakajima, A., Abe, T., Kobayashi, H., Nakata, T., Nakajima, T., Sameshima, K., Kaku, K., et al. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30165-1 · Cited by 50
Targeting gastrointestinal nutrient sensing mechanisms to treat obesity
Norton, M., & Murphy, K. G. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.07.005 · Cited by 22
Sebastiani, A., Greve, F., Gölz, C., Förster, C. Y., Koepsell, H., & Thal, S. C. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14551 · Cited by 21
Metadata
- Authors
- Dobbins, R. L., Greenway, F. L., Chen, L., Liu, Y., Breed, S. L., Andrews, S. M., Wald, J. A., Walker, A., & Smith, C. D.
- Venue
- American Journal of Physiology-Gastrointestinal and Liver Physiology
- Publisher
- American Physiological Society
- Published
- 2015-06-01
- Volume
- 308
- Issue
- 11
- Pages
- G946-G954
- ISSN
- 0193-1857 (ISSN-L)
- 1522-1547
- OpenAlex
- W2157538794
- Cited by
- 107
- References
- 14
- FWCI
- 10.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.